Article PDF
Selected bibliography
Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Fraidakis M, Yoles E, Solomon A, Gepstein R, Katz A, Belkin M, Hadani M, Schwartz M (1998) Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 4:814–821
Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5:49–55
Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, Leibowitz-Amit R, Pevsner S, Akselrod S, Neeman M, Cohen IR, Schwartz M (2000) Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci 20:6421–6430
Hauben E, Ibarra I, Mizrahi T, Barouch R, Agranov E, Schwartz M (2001) Vaccination with a Nogo-A-derived peptide after incomplete spinal cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens. Proc Nat Acad Sci USA 98:15173–15178
Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, Smirnov I, Steinman L, Schwartz M (2001) Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest 108:591–599
Kipnis J, Yoles E, Porat Z, Mor F, Sela M, Cohen IR, Schwartz M (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97:7446–7451
Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, Schwartz M (2001) Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 21:4564–4571
Schori H, Kipnis J, Yoles E, Wolde-Mussie E, Ruiz G, Wheeler LA, Schwartz M (2001) Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci USA 98:3398–3403
Schwartz M, Kipnis J (2001) Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med 7:252–258
References
Goadsby PJ, Lipton RB (1997) A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain 120:193–209
May A, Goadsby PJ (1999) The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metabol 19:115–127
May A, Bahra A, Buchel C, Frackowiak RSJ, Goadsby PJ (1998) Hypothalamic activation in cluster headache attacks. Lancet 351:275–278
May A, Bahra A, Buchel C, Turner R, Goadsby PJ (1999) Functional MRI in spontaneous attacks of SUNCT: short-lasting neuralgiform headache with conjunctival injection and tearing. Ann Neurol 46:791–793
References
Jeisema L C (1987) Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins. J Biol Chem 262:163–168
Farooqui AA, Horrocks LA (2001) Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7:232–245
Farooqui AA, Litski ML, Farooqui T, Horrocks LA (1999) Inhibitors of intracellular phospholipase A2 activity: Their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 49:139–153
Strosznajder J, Strosznajder RP (1989) Guanine nucleotides and fluoride enhance carbachol mediated arachidonic acid release from phosphatidylinositol. J Lipid Med 1:217–229
Pletscher A (1986) Blood platelets as neuronal models: use and limitation. Clin Neuropharmacol 9:344–346
References
Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ (2000) Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol 7:423–426
Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46:100–103
Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R (2000) An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 6:808–811
Buchwald B, Ahangari R, Weishaupt A, Toyka KV (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 51:673–680
Créange A, Lerat H, Meyrignac C, Degos J-D, Gherardi RK, Cesaro P (1998) Treatment of Guillain-Barré syndrome with interferon-β. Lancet 352:368–369
Dalakas MC (2002) Blockade of blocking antibodies in Guillain-Barré syndrome: “unblocking” the mystery of action of intravenous immunoglobulin. Ann Neurol 51:667–668
Feasby TE, Hartung HP (2001) Drain the roots: a new treatment for Guillain-Barré syndrome?. Neurology 57:753–754
French, Cooperative, Group, on, Plasma, Exchange et al. (1987) Efficacy of plasma exchange in Guillain-Barré Syndrome. Ann Neurol 22:753–761
Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. (2001) Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56:758–765
Hartung HP, Kieseier BC, Gold R, Archelos JJ (2000) Intravenous immunoglobulins: impact on effector mechanisms in autoimmune neurological disorders. In: G. Said (ed) Treatment of neurological disorders with intravenous immunoglobulins. Martin Dunitz, London, pp. 1–17
Hughes RA, Raphael JC, Swan AV, van Doorn PA (2001) Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). Cochrane Database Syst Rev 2:CD002063
Hughes RA, van Der Meche FG (2000) Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev, CD001446
Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, et al. (1996) Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 40:181–187
Kieseier BC, Hartung HP (2003) Therapeutic strategies in the Guillain-Barré syndrome. Sem Neurol (in press)
Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001a) Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238
Raphael JC, Chevret S, Hughes RA, Annane D (2001b) Plasma exchange for Guillain-Barré syndrome (Cochrane Review). Cochrane Database Syst Rev 2:CD001798
Ropper AH (1992) The Guillain-Barré syndrome. N Engl J Med 326:1130–1136
Schaller B, Radziwill AJ, Steck A (2001) Successful tretament of Guillain-Barré syndrome with combined administration of interferon-β-la and intravenous immunoglobulin. Eur Neurol 46:167–168
The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41:298–306
The Guillain-Barré syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104
van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326:1123–1129
Visser LH, Van der Meche FG, Van Doorn PA, Meulstee J, Jacobs BC, Oomes PG, et al. (1995) Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 118 (Pt 4): 841–847
Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, et al. (2001) CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 57:774–780
Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al. (2000) Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 47:314–321
Rights and permissions
About this article
Cite this article
Thirteenth meeting of the European Neurological Society 14–18June 2003,Istanbul, Turkey . J Neurol 250 (Suppl 2), II1–II211 (2003). https://doi.org/10.1007/BF03160427
Issue Date:
DOI: https://doi.org/10.1007/BF03160427